Kaposi's sarcoma: Etiology and pathogenesis, inducing factors, causal associations, and treatments: Facts and controversies

Clinics in Dermatology

Volumn 31, Issue 4, 2013, Pages 413-422

  Ruocco, Eleonora ^a   Ruocco, Vincenzo ^a   Tornesello, Maria Lina ^b   Gambardella, Alessio ^a   Wolf, Ronni ^c   Buonaguro, Franco M ^b  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c KAPLAN MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOQUINOLINE DERIVATIVE; ADEFOVIR; ALITRETINOIN; ALPHA INTERFERON; BLEOMYCIN; CHLOROQUINE; CIDOFOVIR; DAUNORUBICIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FOSCARNET; GANCICLOVIR; HYDROXYCHLOROQUINE; IMATINIB; INCYCLINIDE; INFLIXIMAB; INTERLEUKIN 12; IRINOTECAN; NAVELBINE; PACLITAXEL; PROTEIN MDM2; PROTEIN P53; TENIPOSIDE; THALIDOMIDE; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE;

ARTICLE; CANCER RADIOTHERAPY; CONTINUOUS INFUSION; CRYOTHERAPY; DISEASE ASSOCIATION; ELECTROCHEMOTHERAPY; ENVIRONMENTAL FACTOR; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; HEREDITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN HERPESVIRUS 8; IMMUNE DEFICIENCY; INDIVIDUALIZATION; KAPOSI SARCOMA; LYMPHATIC SYSTEM DISEASE; MALARIA; MEDICAL DECISION MAKING; PATHOGENESIS; PATIENT CARE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PRIORITY JOURNAL; SKIN SURGERY; TUMOR SUPPRESSOR GENE;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTINEOPLASTIC AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTIVIRAL AGENTS; DRUG THERAPY; HERPESVIRUS 8, HUMAN; HUMANS; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS; SARCOMA, KAPOSI; SEXUAL BEHAVIOR;

EID: 84879567163     PISSN: 0738081X     EISSN: 18791131     Source Type: Journal    
DOI: 10.1016/j.clindermatol.2013.01.008     Document Type: Article

References (117)

1. Kaposi M. Idiopathisches multiples Pigmentsarkom der Haut. Arch Dermatol Syph 1872, 4:265-273.
2. Thijs A. L'angiosarcomatose de Kaposi au Congo belge et au Ruanda-Urundi. Ann Soc Belge Med Trop (1920) 1957, 37:295-308.
3. Oettle A.G. Geographical and racial differences in the frequency of Kaposi's sarcoma as evidence of environmental or genetic causes. Acta Unio Int Contra Cancrum 1962, 18:330-363.
4. Stribling J., Weitzner S., Smith G.V. Kaposi's sarcoma in renal allograft recipients. Cancer 1978, 42:442-446.
5. Safai B., Mike V., Giraldo G., Beth E., Good R.A. Association of Kaposi's sarcoma with second primary malignancies: possible etiopathogenic implications. Cancer 1980, 45:1472-1479.
6. Hymes K.B., Cheung T., Greene J.B., et al. Kaposi's sarcoma in homosexual men-a report of eight cases. Lancet 1981, 2:598-600.
7. Beral V., Peterman T.A., Berkelman R.L., Jaffe H.W. Kaposi's sarcoma among persons with AIDS: a sexually transmitted infection?. Lancet 1990, 335:123-128.
8. Giraldo G., Beth E., Buonaguro F.M. Kaposi's sarcoma: a natural model of interrelationships between viruses, immunologic responses, genetics, and oncogenesis. Antibiot Chemother 1983, 32:1-11.
9. Giraldo G., Beth E., Coeur P., Vogel C.L., Dhru D.S. Kaposi's sarcoma: a new model in the search for viruses associated with human malignancies. J Natl Cancer Inst 1972, 49:1495-1507.
10. Giraldo G., Beth E., Haguenau F. Herpes-type virus particles in tissue culture of Kaposi's sarcoma from different geographic regions. J Natl Cancer Inst 1972, 49:1509-1526.
11. Giraldo G., Beth E., Huang E.S. Kaposi's sarcoma and its relationship to cytomegalovirus (CMV). III. CMV DNA and CMV early antigens in Kaposi's sarcoma. Int J Cancer 1980, 26:23-29.
12. Chang Y., Cesarman E., Pessin M.S., et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 1994, 266:1865-1869.
13. Buonaguro F.M., Tornesello M.L., Beth-Giraldo E., et al. Herpesvirus-like DNA sequences detected in endemic, classic, iatrogenic and epidemic Kaposi's sarcoma (KS) biopsies. Int J Cancer 1996, 65:25-28.
14. Casper C., Carrell D., Miller K.G., et al. HIV serodiscordant sex partners and the prevalence of human herpesvirus 8 infection among HIV negative men who have sex with men: baseline data from the EXPLORE Study. Sex Transm Infect 2006, 82:229-235.
15. Dukers N.H., Rezza G. Human herpesvirus 8 epidemiology: what we do and do not know. AIDS 2003, 17:1717-1730.
16. Whitby D., Luppi M., Barozzi P., Boshoff C., Weiss R.A., Torelli G. Human herpesvirus 8 seroprevalence in blood donors and lymphoma patients from different regions of Italy. J Natl Cancer Inst 1998, 90:395-397.
17. Engels E.A., Sinclair M.D., Biggar R.J., et al. Latent class analysis of human herpesvirus 8 assay performance and infection prevalence in sub-saharan Africa and Malta. Int J Cancer 2000, 88:1003-1008.
18. De Sanjose S., Mbisa G., Perez-Alvarez S., et al. Geographic variation in the prevalence of Kaposi sarcoma-associated herpesvirus and risk factors for transmission. J Infect Dis 2009, 199:1449-1456.
19. Szajerka T., Jablecki J. Kaposi's sarcoma revisited. AIDS Rev 2007, 9:230-236.
20. Zong J.C., Kajumbula H., Boto W., Hayward G.S. Evaluation of global clustering patterns and strain variation over an extended ORF26 gene locus from Kaposi's sarcoma herpesvirus. J Clin Virol 2007, 40:19-25.
21. Zong J.C., Ciufo D.M., Alcendor D.J., et al. High-level variability in the ORF-K1 membrane protein gene at the left end of the Kaposi's sarcoma-associated herpesvirus genome defines four major virus subtypes and multiple variants or clades in different human populations. J Virol 1999, 73:4156-4170.
22. Poole L.J., Zong J.C., Ciufo D.M., et al. Comparison of genetic variability at multiple loci across the genomes of the major subtypes of Kaposi's sarcoma-associated herpesvirus reveals evidence for recombination and for two distinct types of open reading frame K15 alleles at the right-hand end. J Virol 1999, 73:6646-6660.
23. Biggar R.J., Whitby D., Marshall V., Linhares A.C., Black F. Human herpesvirus 8 in Brazilian Amerindians: a hyperendemic population with a new subtype. J Infect Dis 2000, 181:1562-1568.
24. Kasolo F.C., Monze M., Obel N., Anderson R.A., French C., Gompels U.A. Sequence analyses of human herpesvirus-8 strains from both African human immunodeficiency virus-negative and -positive childhood endemic Kaposi's sarcoma show a close relationship with strains identified in febrile children and high variation in the K1 glycoprotein. J Gen Virol 1998, 79:3055-3065.
25. Kajumbula H., Wallace R.G., Zong J.C., et al. Ugandan Kaposi's sarcoma-associated herpesvirus phylogeny: evidence for cross-ethnic transmission of viral subtypes. Intervirology 2006, 49:133-143.
26. Mancuso R., Biffi R., Valli M., et al. HHV8 a subtype is associated with rapidly evolving classic Kaposi's sarcoma. J Med Virol 2008, 80:2153-2160.
27. Whitby D., Marshall V.A., Bagni R.K., et al. Genotypic characterization of Kaposi's sarcoma-associated herpesvirus in asymptomatic infected subjects from isolated populations. J Gen Virol 2004, 85:155-163.
28. Tornesello M.L., Biryahwaho B., Downing R., et al. Human herpesvirus type 8 variants circulating in Europe, Africa and North America in classic, endemic and epidemic Kaposi's sarcoma lesions during pre-AIDS and AIDS era. Virology 2010, 398:280-289.
29. Jalilvand S., Tornesello M.L., Buonaguro F.M., et al. Molecular epidemiology of human herpesvirus 8 variants in Kaposi's sarcoma from Iranian patients. Virus Res 2012, 163:644-649.
30. Schwartz R.A. Kaposi's sarcoma: an update. J Surg Oncol 2004, 87:146-151.
31. Mbulaiteye S.M., Engels E.A. Kaposi's sarcoma risk among transplant recipients in the United States (1993-2003). Int J Cancer 2006, 119:2685-2691.
32. Pfeiffer R.M., Wheeler W.A., Mbisa G., et al. Geographic heterogeneity of prevalence of the human herpesvirus 8 in sub-Saharan Africa: clues about etiology. Ann Epidemiol 2010, 20:958-963.
33. Goedert J.J., Calamusa G., Dazzi C., et al. Risk of classic Kaposi sarcoma with exposures to plants and soils in Sicily. Infect Agent Cancer 2010, 5:23.
34. Brown E.E., Fallin M.D., Goedert J.J., et al. A common genetic variant in FCGR3A-V158F and risk of Kaposi sarcoma herpesvirus infection and classic Kaposi sarcoma. Cancer Epidemiol Biomarkers Prev 2005, 14:633-637.
35. Si H., Robertson E.S. Kaposi's sarcoma-associated herpesvirus-encoded latency-associated nuclear antigen induces chromosomal instability through inhibition of p53 function. J Virol 2006, 80:697-709.
36. Jin S., Levine A.J. The p53 functional circuit. J Cell Sci 2001, 114:4139-4140.
37. Petitjean A., Achatz M.I., Borresen-Dale A.L., Hainaut P., Olivier M. TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene 2007, 26:2157-2165.
38. Friborg J., Kong W., Hottiger M.O., Nabel G.J. p53 inhibition by the LANA protein of KSHV protects against cell death. Nature 1999, 402:889-894.
39. Lee H.R., Toth Z., Shin Y.C., et al. Kaposi's sarcoma-associated herpesvirus viral interferon regulatory factor 4 targets MDM2 to deregulate the p53 tumor suppressor pathway. J Virol 2009, 83:6739-6747.
40. Rayburn E., Zhang R., He J., Wang H. MDM2 and human malignancies: expression, clinical pathology, prognostic markers, and implications for chemotherapy. Curr Cancer Drug Targets 2005, 5:27-41.
41. Freedman D.A., Levine A.J. Regulation of the p53 protein by the MDM2 oncoprotein-thirty-eighth G.H.A. Clowes Memorial Award Lecture. Cancer Res 1999, 59:1-7.
42. Leach F.S., Tokino T., Meltzer P., et al. p53 Mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res 1993, 53:2231-2234.
43. Bond G.L., Hu W., Bond E.E., et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 2004, 119:591-602.
44. Arva N.C., Gopen T.R., Talbott K.E., et al. A chromatin-associated and transcriptionally inactive p53-Mdm2 complex occurs in mdm2 SNP309 homozygous cells. J Biol Chem 2005, 280:26776-26787.
45. Bougeard G., Baert-Desurmont S., Tournier I., et al. Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome. J Med Genet 2006, 43:531-533.
46. Ruijs M.W., Schmidt M.K., Nevanlinna H. R et al. The single-nucleotide polymorphism 309 in the MDM2 gene contributes to the Li-Fraumeni syndrome and related phenotypes. Eur J Hum Genet 2007, 15:110-114.
47. Bond G.L., Hirshfield K.M., Kirchhoff T., et al. MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner. Cancer Res 2006, 66:5104-5110.
48. Lind H., Zienolddiny S., Ekstrom P.O., Skaug V., Haugen A. Association of a functional polymorphism in the promoter of the MDM2 gene with risk of nonsmall cell lung cancer. Int J Cancer 2006, 119:718-721.
49. Menin C., Scaini M.C., De Salvo G.L., et al. Association between MDM2-SNP309 and age at colorectal cancer diagnosis according to p53 mutation status. J Natl Cancer Inst 2006, 98:285-288.
50. Tornesello M.L., Buonaguro L., Cristillo M., et al. MDM2 and CDKN1A gene polymorphisms and risk of Kaposi's sarcoma in African and Caucasian patients. Biomarkers 2011, 16:42-50.
51. Gaidano G., Castanos-Velez E., Biberfeld P. Lymphoid disorders associated with HHV-8/KSHV infection: facts and contentions. Med Oncol 1999, 16:8-12.
52. Boulanger E., Marchio A., Hong S.S., Pineau P. Mutational analysis of TP53, PTEN, PIK3CA and CTNNB1/beta-catenin genes in human herpesvirus 8-associated primary effusion lymphoma. Haematologica 2009, 94:1170-1174.
53. Davies J.N., Knowelden J., Wilson B.A. Incidence rates of cancer in Kyandondo County, Uganda, 1954-1960. J Natl Cancer Inst 1965, 35:789-821.
54. Templeton A.C., Buxton E., Bianchi A. Cancer in Kyadondo County, Uganda, 1968-70. J Natl Cancer Inst 1972, 48:865-874.
55. Wabinga H.R., Parkin D.M., Wabwire-Mangen F., Mugerwa J.W. Cancer in Kampala, Uganda, in 1989-91: changes in incidence in the era of AIDS. Int J Cancer 1993, 54:26-36.
56. Dedicoat M., Newton R. Review of the distribution of Kaposi's sarcoma-associated herpesvirus (KSHV) in Africa in relation to the incidence of Kaposi's sarcoma. Br J Cancer 2003, 88:1-3.
57. Haverkos H.W. Multifactorial etiology of Kaposi' sarcoma: a hypothesis. J Biosci 2008, 33:643-651.
58. Ziegler J.L. Endemic Kaposi's sarcoma in Africa and local volcanic soils. Lancet 1993, 342:1348-1351.
59. Ruocco V., Astarita C., Guerrera V., et al. Kaposi's sarcoma on a lymphedematous immunocompromised limb. Int J Dermatol 1984, 23:56-60.
60. Ruocco V. Linfostasi: importante fattore patogenetico nel sarcoma di Kaposi classico. Ann Ital Dermatol Clin Sper 1992, 46:153-160.
61. Ruocco V., Satriano R.A., Bernabò R., Astarita C. Anomalies régionales des voies lymphatiques et de la réponse au D.N.C.B. dans le sarcome de Kaposi classique. Ann Dermatol Venereol 1985, 112:283-286.
62. Schwartz R.A., Cohen J.B., Watson R.A., et al. Penile Kaposi's sarcoma preceded by chronic penile lymphoedema. Br J Dermatol 2000, 142:153-156.
63. Hengge U.R., Stocks K., Goos M. Acquired immune deficiency syndrome-related hyperkeratotic Kaposi's sarcoma with severe lymphoedema: report of five cases. Br J Dermatol 2000, 142:501-505.
64. Witte M.H., Stuntz M., Witte C.L. Kaposi's sarcoma. A lymphologic perspective. Int J Dermatol 1989, 28:561-570.
65. Ruocco V., Schwartz R.A., Ruocco E. Lymphedema: an immunologically vulnerable site for development of neoplasms. J Am Acad Dermatol 2002, 47:124-127.
66. Kostaki M., Pham X.C., Toutous-Trellu L., et al. Kaposi's sarcoma after repeated surgical procedures in an immunocompetent patient: the lymphatic hypothesis. Dermatology 2010, 221:313-316.
67. Ruocco V., Brasiello M., Szolnoky G., Brunetti G., Ruocco E. Kaposi's sarcoma restricted to an immunocompromised district. Dermatology 2011, 223:211-212.
68. Haverkos H.W. Viruses, chemicals and co-carcinogenesis. Oncogene 2004, 23:6492-6499.
69. zur Hausen H. Viruses as tumor initiators and tumor promoters. Haematol Blood Transfus 1985, 29:306-307.
70. Buonaguro F.M., Beth-Giraldo E., Giraldo G. Prospected etiopathogenic mechanisms of AIDS-associated tumors. Antibiot Chemother 1991, 43:96-114.
71. Cuzick J. Viruses and cancer. J Epidemiol Biostat 2000, 5:143-152.
72. Mesri E.A., Cesarman E., Boshoff C. Kaposi's sarcoma and its associated herpesvirus. Nat Rev Cancer 2010, 10:707-719.
73. Haverkos H.W., Kopstein A.N., Wilson H., Drotman P. Nitrite inhalants: history, epidemiology, and possible links to AIDS. Environ Health Perspect 1994, 102:858-861.
74. Mirvish S.S., Williamson J., Babcook D., Chen S.C. Mutagenicity of iso-butyl nitrite vapor in the Ames test and some relevant chemical properties, including the reaction of iso-butyl nitrite with phosphate. Environ Mol Mutagen 1993, 21:247-252.
75. Buonaguro F.M., Tomesello M.L., Buonaguro L., et al. Kaposi's sarcoma: aetiopathogenesis, histology and clinical features. J Eur Acad Dermatol Venereol 2003, 17:138-154.
76. Schwartz R.A., Micali G., Nasca M.R., Scuderi L. Kaposi sarcoma: a continuing conundrum. J Am Acad Dermatol 2008, 59:179-206.
77. WHO. Malaria treatment guidelines 2010. Washington DC: WHO.
78. Sayang C., Gausseres M., Vernazza-Licht N., Malvy D., Bley D., Millet P. Treatment of malaria from monotherapy to artemisinin-based combination therapy by health professionals in rural health facilities in southern Cameroon. Malar J 2009, 8:174.
79. UMSP sentinel site malaria surveillance report July 2010 2010, UMSP.
80. Whitby D., Marshall V.A., Bagni R.K., et al. Reactivation of Kaposi's sarcoma-associated herpesvirus by natural products from Kaposi's sarcoma endemic regions. Int J Cancer 2007, 120:321-328.
81. Ruocco V., Ruocco E., Schwartz R.A., Janniger C.K. Kaposi sarcoma and quinine: a potentially overlooked triggering factor in millions of Africans. J Am Acad Dermatol 2011, 64:434-436.
82. Katz S.J., Russell A.S. Re-evaluation of antimalarials in treating rheumatic diseases: re-appreciation and insights into new mechanisms of action. Curr Opin Rheumatol 2011, 23:278-281.
83. Pappaioanou M., Fishbein D.B., Dreesen D.W., et al. Antibody response to preexposure human diploid-cell rabies vaccine given concurrently with chloroquine. N Engl J Med 1986, 314:280-284.
84. Trilla A., Trilla G., Daer C. The 1918 "Spanish flu" in Spain. Clin Infect Dis 2008, 47:668-673.
85. Ruocco V., Sacerdoti G., Astarita C. Does quinine facilitate AIDS?. Antibiot Chemother 1983, 32:159-160.
86. Bilen N., Bayramgurler D., Aydeniz B., Apaydin R., Ozkara S.K. Possible causal role of lisinopril in a case of Kaposi's sarcoma. Br J Dermatol 2002, 147:1042-1044.
87. Dervis E., Demirkesen C. Kaposi's sarcoma in a patient with psoriasis vulgaris. Acta Dermatovenerol Alp Panonica Adriat 2010, 19:31-34.
88. Dalbeth N., Edwards J., Fairchild S., Callan M., Hall F.C. The non-thiol angiotensin-converting enzyme inhibitor quinapril suppresses inflammatory arthritis. Rheumatology (Oxford) 2005, 44:24-31.
89. Murohara T., Asahara T., Silver M., et al. Nitric oxide synthase modulates angiogenesis in response to tissue ischemia. J Clin Invest 1998, 101:2567-2578.
90. Ziche M., Morbidelli L., Choudhuri R., et al. Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis. J Clin Invest 1997, 99:2625-2634.
91. Hayashi R., Yamashita N., Matsui S., et al. Bradykinin stimulates IL-6 and IL-8 production by human lung fibroblasts through ERK- and p38 MAPK-dependent mechanisms. Eur Respir J 2000, 16:452-458.
92. Sasaki K., Tsuno N.H., Sunami E., et al. Chloroquine potentiates the anti-cancer effect of 5-fluorouracil on colon cancer cells. BMC Cancer 2010, 10:370.
93. Wang Y., Peng R.Q., Li D.D., et al. Chloroquine enhances the cytotoxicity of topotecan by inhibiting autophagy in lung cancer cells. Chin J Cancer 2011, 30:690-700.
94. Glick D., Barth S., Macleod K.F. Autophagy: cellular and molecular mechanisms. J Pathol 2010, 221:3-12.
95. Wozniacka A., Lesiak A., Boncela J., Smolarczyk K., McCauliffe D.P., Sysa-Jedrzejowska A. The influence of antimalarial treatment on IL-1beta, IL-6 and TNF-alpha mRNA expression on UVB-irradiated skin in systemic lupus erythematosus. Br J Dermatol 2008, 159:1124-1130.
96. Carneiro J.R., Fuzii H.T., Kayser C., et al. IL-2, IL-5, TNF-alpha and IFN-gamma mRNA expression in epidermal keratinocytes of systemic lupus erythematosus skin lesions. Clinics (Sao Paulo) 2011, 66:77-82.
97. Rolain J.M., Colson P., Raoult D. Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century. Int J Antimicrob Agents 2007, 30:297-308.
98. Wolf R., Tufano M.A., Ruocco V., et al. Quinine sulfate inhibits invasion of some bacterial skin pathogens. Int J Dermatol 2006, 45:661-663.
99. Baroni A., Paoletti I., Ruocco E., et al. Antiviral effects of quinine sulfate on HSV-1 HaCat cells infected: analysis of the molecular mechanisms involved. J Dermatol Sci 2007, 47:253-255.
100. Wolf R., Baroni A., Greco R., et al. Quinine sulfate and HSV replication. Dermatol Online J 2003, 9:3.
101. Akula S.M., Naranatt P.P., Walia N.S., Wang F.Z., Fegley B., Chandran B. Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) infection of human fibroblast cells occurs through endocytosis. J Virol 2003, 77:7978-7990.
102. Murakami-Mori K., Mori S., Bonavida B., Nakamura S. Implication of TNF receptor-I-mediated extracellular signal-regulated kinases 1 and 2 (ERK1/2) activation in growth of AIDS-associated Kaposi's sarcoma cells: a possible role of a novel death domain protein MADD in TNF-alpha-induced ERK1/2 activation in Kaposi's sarcoma cells. J Immunol 1999, 162:3672-3679.
103. Ursini F., Naty S., Mazzei V., Spagnolo F., Grembiale R.D. Kaposi's sarcoma in a psoriatic arthritis patient treated with infliximab. Int Immunopharmacol 2010, 10:827-828.
104. Vogt B., Frey F.J. Inhibition of angiogenesis in Kaposi's sarcoma by captopril. Lancet 1997, 349:1148.
105. Johnsen S.A., Aurell M. Immunosuppressive action of captopril blocked by prostaglandin synthetase inhibitor. Lancet 1981, 1:1005.
106. Fabre J.E., Rivard A., Magner M., Silver M., Isner J.M. Tissue inhibition of angiotensin-converting enzyme activity stimulates angiogenesis in vivo. Circulation 1999, 99:3043-3049.
107. Fukuzawa M., Satoh J., Sagara M., et al. Angiotensin converting enzyme inhibitors suppress production of tumor necrosis factor-alpha in vitro and in vivo. Immunopharmacology 1997, 36:49-55.
108. Curatolo P., Quaglino P., Marenco F., et al. Electrochemotherapy in the treatment of Kaposi sarcoma cutaneous lesions: a two-center prospective phase II trial. Ann Surg Oncol 2012, 19:192-198.
109. Becker G., Bottke D. Radiotherapy in the management of Kaposi's sarcoma. Onkologie 2006, 29:329-333.
110. Spano J.P., Costagliola D., Katlama C., Mounier N., Oksenhendler E., Khayat D. AIDS-related malignancies: state of the art and therapeutic challenges. J Clin Oncol 2008, 26:4834-4842.
111. Leidner R.S., Aboulafia D.M. Recrudescent Kaposi's sarcoma after initiation of HAART: a manifestation of immune reconstitution syndrome. AIDS Patient Care STDS 2005, 19:635-644.
112. Krown S.E., Northfelt D.W., Osoba D., Stewart J.S. Use of liposomal anthracyclines in Kaposi's sarcoma. Semin Oncol 2004, 31:36-52.
113. Vaccher E., di Gennaro G., Simonelli C., Schioppa O., Tirelli U. Evidence of activity of Irinotecan in patients with advanced AIDS-related Kaposi's sarcoma. AIDS 2005, 19:1915-1916.
114. Dezube B.J., Krown S.E., Lee J.Y., Bauer K.S., Aboulafia D.M. Randomized phase II trial of matrix metalloproteinase inhibitor COL-3 in AIDS-related Kaposi's sarcoma: an AIDS Malignancy Consortium Study. J Clin Oncol 2006, 24:1389-1394.
115. Little R.F., Wyvill K.M., Pluda J.M., et al. Activity of thalidomide in AIDS-related Kaposi's sarcoma. J Clin Oncol 2000, 18:2593-2602.
116. Yarchoan R., Pluda J.M., Wyvill K.M., et al. Treatment of AIDS-related Kaposi's sarcoma with interleukin-12: rationale and preliminary evidence of clinical activity. Crit Rev Immunol 2007, 27:401-414.
117. Koon H.B., Bubley G.J., Pantanowitz L., et al. Imatinib-induced regression of AIDS-related Kaposi's sarcoma. J Clin Oncol 2005, 23:982-989.